APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human cytomegalovirus 65 kDa Phosphoprotein

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Human cytomegalovirus 65 kDa Phosphoprotein Market Analysis and Forecast 2026-2032

19 December 2025190 pages

Choose your research edition.

Industry ResearchHuman cytomegalovirus 65 kDa Phosphoprotein Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Human cytomegalovirus 65 kDa Phosphoprotein Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Human cytomegalovirus 65 kDa Phosphoprotein Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human cytomegalovirus 65 kDa Phosphoprotein Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Human cytomegalovirus 65 kDa Phosphoprotein Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Human cytomegalovirus 65 kDa Phosphoprotein market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Human cytomegalovirus 65 kDa Phosphoprotein is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Human cytomegalovirus 65 kDa Phosphoprotein is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Human cytomegalovirus 65 kDa Phosphoprotein is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Human cytomegalovirus 65 kDa Phosphoprotein is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein include Astellas Pharma Inc, Hookipa Biotech AG, Immunomic Therapeutics Inc, Vakzine Projekt Management GmbH, Vaximm AG, VBI Vaccines Inc and Vical Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Human cytomegalovirus 65 kDa Phosphoprotein, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Human cytomegalovirus 65 kDa Phosphoprotein, also provides the sales of main regions and countries. Of the upcoming market potential for Human cytomegalovirus 65 kDa Phosphoprotein, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human cytomegalovirus 65 kDa Phosphoprotein sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Human cytomegalovirus 65 kDa Phosphoprotein market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Human cytomegalovirus 65 kDa Phosphoprotein sales, projected growth trends, production technology, application and end-user industry.

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Company

Astellas Pharma Inc

Hookipa Biotech AG

Immunomic Therapeutics Inc

Vakzine Projekt Management GmbH

Vaximm AG

VBI Vaccines Inc

Vical Inc

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Type

HB-101

ASP-0113

PepVax

CyMVectin

Others

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Application

Hemotaological Tumor

Kidney Transplant Rejection

Brain Tumor

Liver Transplant Rejection

Others

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human cytomegalovirus 65 kDa Phosphoprotein market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human cytomegalovirus 65 kDa Phosphoprotein and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human cytomegalovirus 65 kDa Phosphoprotein.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Human cytomegalovirus 65 kDa Phosphoprotein in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Human cytomegalovirus 65 kDa Phosphoprotein manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human cytomegalovirus 65 kDa Phosphoprotein sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. HB-101 Major Manufacturers Table 3. ASP-0113 Major Manufacturers Table 4. PepVax Major Manufacturers Table 5. CyMVectin Major Manufacturers Table 6. Others Major Manufacturers Table 7. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hemotaological Tumor Major Manufacturers Table 9. Kidney Transplant Rejection Major Manufacturers Table 10. Brain Tumor Major Manufacturers Table 11. Liver Transplant Rejection Major Manufacturers Table 12. Others Major Manufacturers Table 13. Human cytomegalovirus 65 kDa Phosphoprotein Industry Trends Table 14. Human cytomegalovirus 65 kDa Phosphoprotein Industry Drivers Table 15. Human cytomegalovirus 65 kDa Phosphoprotein Industry Opportunities and Challenges Table 16. Human cytomegalovirus 65 kDa Phosphoprotein Industry Restraints Table 17. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2021-2026) & (US$ Million) Table 19. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2027-2032) & (US$ Million) Table 20. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Region (2021-2026) Table 21. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Region (2027-2032) Table 22. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 23. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2021-2026) & (K Units) Table 24. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2027-2032) & (K Units) Table 25. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Region (2021-2026) Table 26. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Region (2027-2032) Table 27. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Manufacturers (2021-2026) Table 29. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Manufacturers (2021-2026) Table 31. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 32. Global Human cytomegalovirus 65 kDa Phosphoprotein Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global Human cytomegalovirus 65 kDa Phosphoprotein Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global Human cytomegalovirus 65 kDa Phosphoprotein Manufacturers, Product Type & Application Table 35. Global Human cytomegalovirus 65 kDa Phosphoprotein Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global Human cytomegalovirus 65 kDa Phosphoprotein by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type (2021-2026) Table 42. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type (2027-2032) Table 43. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 44. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 45. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2027-2032) & (K Units) Table 46. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2021-2026) Table 47. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2027-2032) Table 48. Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Type (2021-2026) & (US$/Unit) Table 49. Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Type (2027-2032) & (US$/Unit) Table 50. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2026) & (US$ Million) Table 52. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2027-2032) & (US$ Million) Table 53. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application (2021-2026) Table 54. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application (2027-2032) Table 55. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 56. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 57. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2027-2032) & (K Units) Table 58. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application (2021-2026) Table 59. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application (2027-2032) Table 60. Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Application (2021-2026) & (US$/Unit) Table 61. Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Application (2027-2032) & (US$/Unit) Table 62. Astellas Pharma Inc Company Information Table 63. Astellas Pharma Inc Business Overview Table 64. Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 66. Astellas Pharma Inc Recent Development Table 67. Hookipa Biotech AG Company Information Table 68. Hookipa Biotech AG Business Overview Table 69. Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 71. Hookipa Biotech AG Recent Development Table 72. Immunomic Therapeutics Inc Company Information Table 73. Immunomic Therapeutics Inc Business Overview Table 74. Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 76. Immunomic Therapeutics Inc Recent Development Table 77. Vakzine Projekt Management GmbH Company Information Table 78. Vakzine Projekt Management GmbH Business Overview Table 79. Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 81. Vakzine Projekt Management GmbH Recent Development Table 82. Vaximm AG Company Information Table 83. Vaximm AG Business Overview Table 84. Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 86. Vaximm AG Recent Development Table 87. VBI Vaccines Inc Company Information Table 88. VBI Vaccines Inc Business Overview Table 89. VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 91. VBI Vaccines Inc Recent Development Table 92. Vical Inc Company Information Table 93. Vical Inc Business Overview Table 94. Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 96. Vical Inc Recent Development Table 97. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2026) & (US$ Million) Table 98. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2027-2032) & (US$ Million) Table 99. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 100. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2027-2032) & (K Units) Table 101. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Type (2021-2026) & (US$/Unit) Table 102. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Type (2027-2032) & (US$/Unit) Table 103. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2026) & (US$ Million) Table 104. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2027-2032) & (US$ Million) Table 105. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 106. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2027-2032) & (K Units) Table 107. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Application (2021-2026) & (US$/Unit) Table 108. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Application (2027-2032) & (US$/Unit) Table 109. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 111. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 112. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 113. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 114. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2027-2032) & (K Units) Table 115. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Country (2021-2026) & (US$/Unit) Table 116. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Country (2027-2032) & (US$/Unit) Table 117. United States Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 118. Canada Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 119. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2026) & (US$ Million) Table 120. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2027-2032) & (US$ Million) Table 121. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 122. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2027-2032) & (K Units) Table 123. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Type (2021-2026) & (US$/Unit) Table 124. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Type (2027-2032) & (US$/Unit) Table 125. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2026) & (US$ Million) Table 126. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2027-2032) & (US$ Million) Table 127. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 128. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2027-2032) & (K Units) Table 129. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Application (2021-2026) & (US$/Unit) Table 130. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Application (2027-2032) & (US$/Unit) Table 131. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 133. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 134. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 135. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 136. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2027-2032) & (K Units) Table 137. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Country (2021-2026) & (US$/Unit) Table 138. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Country (2027-2032) & (US$/Unit) Table 139. Germany Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 140. France Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 141. U.K. Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 142. Italy Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 143. Netherlands Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 144. China Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2026) & (US$ Million) Table 145. China Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2027-2032) & (US$ Million) Table 146. China Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 147. China Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2027-2032) & (K Units) Table 148. China Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Type (2021-2026) & (US$/Unit) Table 149. China Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Type (2027-2032) & (US$/Unit) Table 150. China Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2026) & (US$ Million) Table 151. China Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2027-2032) & (US$ Million) Table 152. China Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 153. China Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2027-2032) & (K Units) Table 154. China Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Application (2021-2026) & (US$/Unit) Table 155. China Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Application (2027-2032) & (US$/Unit) Table 156. Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2026) & (US$ Million) Table 157. Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2027-2032) & (US$ Million) Table 158. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 159. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2027-2032) & (K Units) Table 160. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Type (2021-2026) & (US$/Unit) Table 161. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Type (2027-2032) & (US$/Unit) Table 162. Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2026) & (US$ Million) Table 163. Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2027-2032) & (US$ Million) Table 164. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 165. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2027-2032) & (K Units) Table 166. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Application (2021-2026) & (US$/Unit) Table 167. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Application (2027-2032) & (US$/Unit) Table 168. Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 169. Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 170. Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 171. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 172. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 173. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2027-2032) & (K Units) Table 174. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Country (2021-2026) & (US$/Unit) Table 175. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Country (2027-2032) & (US$/Unit) Table 176. Japan Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 177. South Korea Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 178. India Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 179. Australia Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 180. China Taiwan Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 181. Southeast Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 182. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2026) & (US$ Million) Table 183. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2027-2032) & (US$ Million) Table 184. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 185. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2027-2032) & (K Units) Table 186. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Type (2021-2026) & (US$/Unit) Table 187. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Type (2027-2032) & (US$/Unit) Table 188. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2026) & (US$ Million) Table 189. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2027-2032) & (US$ Million) Table 190. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 191. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2027-2032) & (K Units) Table 192. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Application (2021-2026) & (US$/Unit) Table 193. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Application (2027-2032) & (US$/Unit) Table 194. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 195. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 196. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 197. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 198. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 199. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2027-2032) & (K Units) Table 200. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Country (2021-2026) & (US$/Unit) Table 201. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Country (2027-2032) & (US$/Unit) Table 202. Brazil Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 203. Argentina Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 204. Chile Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 205. Colombia Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 206. Peru Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 207. Saudi Arabia Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 208. Israel Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 209. UAE Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 210. Turkey Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 211. Iran Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 212. Egypt Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Table 213. Key Raw Materials Table 214. Raw Materials Key Suppliers Table 215. Human cytomegalovirus 65 kDa Phosphoprotein Distributors List Table 216. Human cytomegalovirus 65 kDa Phosphoprotein Customers List Table 217. Research Programs/Design for This Report Table 218. Authors List of This Report Table 219. Secondary Sources Table 220. Primary Sources List of Figures Figure 1. Human cytomegalovirus 65 kDa Phosphoprotein Image Figure 2. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Share 2021 VS 2025 VS 2032 Figure 4. HB-101 Image Figure 5. ASP-0113 Image Figure 6. PepVax Image Figure 7. CyMVectin Image Figure 8. Others Image Figure 9. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hemotaological Tumor Image Figure 12. Kidney Transplant Rejection Image Figure 13. Brain Tumor Image Figure 14. Liver Transplant Rejection Image Figure 15. Others Image Figure 16. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Figure 18. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Region (2021-2032) Figure 21. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (2021-2032) & (K Units) Figure 22. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 23. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico Human cytomegalovirus 65 kDa Phosphoprotein Sales YoY (2021-2032) & (K Units) Figure 25. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales YoY (2021-2032) & (K Units) Figure 26. China Human cytomegalovirus 65 kDa Phosphoprotein Sales YoY (2021-2032) & (K Units) Figure 27. Asia (Excluding China) Human cytomegalovirus 65 kDa Phosphoprotein Sales YoY (2021-2032) & (K Units) Figure 28. South America, Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales YoY (2021-2032) & (K Units) Figure 29. Global Human cytomegalovirus 65 kDa Phosphoprotein Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Human cytomegalovirus 65 kDa Phosphoprotein Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type (2021-2032) Figure 35. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2021-2032) Figure 38. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application (2021-2032) Figure 41. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 42. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application (2021-2032) Figure 44. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Type (2021-2032) Figure 45. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Type (2021-2032) Figure 46. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Application (2021-2032) Figure 47. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Application (2021-2032) Figure 48. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Country (2021-2032) Figure 49. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Country (2021-2032) Figure 50. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Type (2021-2032) Figure 51. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Type (2021-2032) Figure 52. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Application (2021-2032) Figure 53. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Application (2021-2032) Figure 54. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Country (2021-2032) Figure 55. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Country (2021-2032) Figure 56. China Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Type (2021-2032) Figure 57. China Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Type (2021-2032) Figure 58. China Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Application (2021-2032) Figure 59. China Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Application (2021-2032) Figure 60. Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Type (2021-2032) Figure 61. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Type (2021-2032) Figure 62. Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Application (2021-2032) Figure 63. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Application (2021-2032) Figure 64. Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Country (2021-2032) Figure 65. Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Country (2021-2032) Figure 66. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Type (2021-2032) Figure 67. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Type (2021-2032) Figure 68. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Application (2021-2032) Figure 69. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Application (2021-2032) Figure 70. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Country (2021-2032) Figure 71. SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Country (2021-2032) Figure 72. Human cytomegalovirus 65 kDa Phosphoprotein Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Human cytomegalovirus 65 kDa Phosphoprotein Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • HB-101
  • ASP-0113
  • PepVax
  • CyMVectin
  • Others
Applications
  • Hemotaological Tumor
  • Kidney Transplant Rejection
  • Brain Tumor
  • Liver Transplant Rejection
  • Others
Companies covered
  • Astellas Pharma Inc
  • Hookipa Biotech AG
  • Immunomic Therapeutics Inc
  • Vakzine Projekt Management GmbH
  • Vaximm AG
  • VBI Vaccines Inc
  • Vical Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Human cytomegalovirus 65 kDa Phosphoprotein Market by Type
  3. 1.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 HB-101
  5. 1.2.3 ASP-0113
  6. 1.2.4 PepVax
  7. 1.2.5 CyMVectin
  8. 1.2.6 Others
  9. 1.3 Human cytomegalovirus 65 kDa Phosphoprotein Market by Application
  10. 1.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hemotaological Tumor
  12. 1.3.3 Kidney Transplant Rejection
  13. 1.3.4 Brain Tumor
  14. 1.3.5 Liver Transplant Rejection
  15. 1.3.6 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Human cytomegalovirus 65 kDa Phosphoprotein Market Dynamics
  1. 2.1 Human cytomegalovirus 65 kDa Phosphoprotein Industry Trends
  2. 2.2 Human cytomegalovirus 65 kDa Phosphoprotein Industry Drivers
  3. 2.3 Human cytomegalovirus 65 kDa Phosphoprotein Industry Opportunities and Challenges
  4. 2.4 Human cytomegalovirus 65 kDa Phosphoprotein Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region
  3. 3.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2021-2026)
  5. 3.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2027-2032)
  6. 3.2.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region
  9. 3.4.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2021-2026)
  11. 3.4.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2027-2032)
  12. 3.4.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Manufacturers
  2. 4.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Manufacturers
  6. 4.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Human cytomegalovirus 65 kDa Phosphoprotein Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Human cytomegalovirus 65 kDa Phosphoprotein Manufacturers, Product Type & Application
  13. 4.7 Global Human cytomegalovirus 65 kDa Phosphoprotein Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market CR5 and HHI
  16. 4.8.2 2025 Human cytomegalovirus 65 kDa Phosphoprotein Tier 1, Tier 2, and Tier 3
5 Human cytomegalovirus 65 kDa Phosphoprotein Market by Type
  1. 5.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type
  2. 5.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type
  6. 5.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2021-2032)
  9. 5.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Type
6 Human cytomegalovirus 65 kDa Phosphoprotein Market by Application
  1. 6.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application
  2. 6.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application
  6. 6.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application (2021-2032)
  9. 6.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Application
7 Company Profiles
  1. 7.1 Astellas Pharma Inc
  2. 7.1.1 Astellas Pharma Inc Company Information
  3. 7.1.2 Astellas Pharma Inc Business Overview
  4. 7.1.3 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  6. 7.1.5 Astellas Pharma Inc Recent Developments
  7. 7.2 Hookipa Biotech AG
  8. 7.2.1 Hookipa Biotech AG Company Information
  9. 7.2.2 Hookipa Biotech AG Business Overview
  10. 7.2.3 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  12. 7.2.5 Hookipa Biotech AG Recent Developments
  13. 7.3 Immunomic Therapeutics Inc
  14. 7.3.1 Immunomic Therapeutics Inc Company Information
  15. 7.3.2 Immunomic Therapeutics Inc Business Overview
  16. 7.3.3 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  18. 7.3.5 Immunomic Therapeutics Inc Recent Developments
  19. 7.4 Vakzine Projekt Management GmbH
  20. 7.4.1 Vakzine Projekt Management GmbH Company Information
  21. 7.4.2 Vakzine Projekt Management GmbH Business Overview
  22. 7.4.3 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  24. 7.4.5 Vakzine Projekt Management GmbH Recent Developments
  25. 7.5 Vaximm AG
  26. 7.5.1 Vaximm AG Company Information
  27. 7.5.2 Vaximm AG Business Overview
  28. 7.5.3 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  30. 7.5.5 Vaximm AG Recent Developments
  31. 7.6 VBI Vaccines Inc
  32. 7.6.1 VBI Vaccines Inc Company Information
  33. 7.6.2 VBI Vaccines Inc Business Overview
  34. 7.6.3 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  36. 7.6.5 VBI Vaccines Inc Recent Developments
  37. 7.7 Vical Inc
  38. 7.7.1 Vical Inc Company Information
  39. 7.7.2 Vical Inc Business Overview
  40. 7.7.3 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  42. 7.7.5 Vical Inc Recent Developments
8 North America
  1. 8.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Type
  2. 8.1.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2032)
  3. 8.1.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2032)
  4. 8.1.3 North America Human cytomegalovirus 65 kDa Phosphoprotein Price by Type (2021-2032)
  5. 8.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Application
  6. 8.2.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2032)
  7. 8.2.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2032)
  8. 8.2.3 North America Human cytomegalovirus 65 kDa Phosphoprotein Price by Application (2021-2032)
  9. 8.3 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country
  10. 8.3.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Human cytomegalovirus 65 kDa Phosphoprotein Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Type
  2. 9.1.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2032)
  3. 9.1.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2032)
  4. 9.1.3 Europe Human cytomegalovirus 65 kDa Phosphoprotein Price by Type (2021-2032)
  5. 9.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Application
  6. 9.2.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2032)
  7. 9.2.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2032)
  8. 9.2.3 Europe Human cytomegalovirus 65 kDa Phosphoprotein Price by Application (2021-2032)
  9. 9.3 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country
  10. 9.3.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Human cytomegalovirus 65 kDa Phosphoprotein Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Type
  2. 10.1.1 China Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2032)
  3. 10.1.2 China Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2032)
  4. 10.1.3 China Human cytomegalovirus 65 kDa Phosphoprotein Price by Type (2021-2032)
  5. 10.2 China Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Application
  6. 10.2.1 China Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2032)
  7. 10.2.2 China Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2032)
  8. 10.2.3 China Human cytomegalovirus 65 kDa Phosphoprotein Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Type
  2. 11.1.1 Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2032)
  3. 11.1.2 Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2032)
  4. 11.1.3 Asia Human cytomegalovirus 65 kDa Phosphoprotein Price by Type (2021-2032)
  5. 11.2 Asia Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Application
  6. 11.2.1 Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2032)
  7. 11.2.2 Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2032)
  8. 11.2.3 Asia Human cytomegalovirus 65 kDa Phosphoprotein Price by Application (2021-2032)
  9. 11.3 Asia Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country
  10. 11.3.1 Asia Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Human cytomegalovirus 65 kDa Phosphoprotein Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Type
  2. 12.1.1 SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Price by Type (2021-2032)
  5. 12.2 SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Application
  6. 12.2.1 SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Price by Application (2021-2032)
  9. 12.3 SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country
  10. 12.3.1 SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Human cytomegalovirus 65 kDa Phosphoprotein Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Human cytomegalovirus 65 kDa Phosphoprotein Value Chain Analysis
  2. 13.1.1 Human cytomegalovirus 65 kDa Phosphoprotein Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Human cytomegalovirus 65 kDa Phosphoprotein Production Mode & Process
  6. 13.2 Human cytomegalovirus 65 kDa Phosphoprotein Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Human cytomegalovirus 65 kDa Phosphoprotein Distributors
  9. 13.2.3 Human cytomegalovirus 65 kDa Phosphoprotein Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst